Ignite Creation Date:
2025-12-24 @ 3:31 PM
Ignite Modification Date:
2026-02-25 @ 6:30 PM
Study NCT ID:
NCT02320292
Status:
TERMINATED
Last Update Posted:
2025-07-09
First Post:
2014-12-15
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma
Sponsor:
Mayo Clinic
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Ann Arbor Stage I Grade 1 Follicular Lymphoma | View |
| None | Ann Arbor Stage I Grade 2 Follicular Lymphoma | View |
| None | Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma | View |
| None | Ann Arbor Stage III Grade 1 Follicular Lymphoma | View |
| None | Ann Arbor Stage III Grade 2 Follicular Lymphoma | View |
| None | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | View |
| None | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | View |
Keywords: